Imoxat

Active Ingredient:: Imidacloprid;moxidectin
Brand:: Imoxat
Origin:: European Union

Imoxat (Imidacloprid;moxidectin)

Imidacloprid/moxidectin, the active ingredient in Imoxat, is an antiparasitic drug presented as a combination formulation for topical or oral use in animals. It targets ectoparasites and endoparasites in companion and livestock species.

GNH India supplies Imoxat as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Imoxat is used to manage parasitic infestations in animals, covering both external and internal parasite families.

Canine heartworm disease: prevents infection by Dirofilaria immitis in dogs.
Flea infestation in dogs and cats: eliminates adult fleas and reduces egg production.
Intestinal nematodes in dogs: treats common roundworm, hookworm and whipworm infections.

How It Works

Imidacloprid acts as a nicotinic acetylcholine receptor agonist in insects, causing overstimulation of the nervous system and paralysis. Moxidectin binds to glutamate‑gated chloride channels in nematodes and arthropods, increasing chloride ion influx, leading to hyperpolarization, paralysis and death of the parasite.

Side Effects

Adverse reactions to Imoxat may vary in frequency and severity.

Common Side Effects

Mild skin irritation at the application site.
Transient vomiting or nausea.
Diarrhea or soft stools.
Temporary lethargy or reduced activity.

Serious or Rare Side Effects

Severe allergic reactions, including facial swelling and hives.
Anaphylaxis with respiratory distress.
Neurological signs such as tremors or seizures.
Profound vomiting or hemorrhagic diarrhea.

Precautions & Warnings

When using Imoxat, consider the following precautions to ensure safe administration.

Pregnancy: consult a veterinarian before use in breeding animals.
Age: not recommended for puppies or kittens younger than eight weeks.
Concurrent medications: avoid simultaneous use with other ectoparasitic agents without veterinary guidance.
Known hypersensitivity: discontinue use and seek veterinary care if allergic signs appear.
Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Imoxat may interact with other veterinary medicines; monitor the following combinations.

Major Interactions (Avoid)

Co‑administration with other macrocyclic lactones (e.g., ivermectin) can increase neurotoxicity risk.
Use with organophosphate insecticides may potentiate cholinergic toxicity.

Moderate Interactions (Monitor Closely)

Concurrent use with other nicotinic acetylcholine receptor agonists may enhance nervous system side effects.
Combination with corticosteroids may mask early allergic reactions.
Concurrent administration with certain antibiotics (e.g., macrolides) may alter drug metabolism.

Frequently Asked Questions

Imoxat is a veterinary antiparasitic product that combines imidacloprid and moxidectin to control fleas, ticks, heartworm and common intestinal nematodes in dogs and cats. It is used by veterinarians to prevent and treat these external and internal parasites in companion animals.

Imidacloprid binds to nicotinic acetylcholine receptors in insects, causing continuous nerve stimulation and paralysis. Moxidectin targets glutamate‑gated chloride channels in nematodes and arthropods, increasing chloride influx, which hyperpolarises the cell membrane and leads to parasite paralysis and death.

The dose of Imoxat is determined by the prescribing veterinarian based on the animal’s species, weight, age and the specific parasites being treated. The product label provides dosing guidelines, but the final regimen is set by the animal health professional.

Safety data for Imoxat in breeding, pregnant or lactating animals are limited. Veterinarians should evaluate the risk‑benefit ratio and may recommend alternative treatments if there are concerns about fetal or neonatal exposure.

To order Imoxat, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imoxat combines two active ingredients, offering broad‑spectrum activity against both ectoparasites (via imidacloprid) and endoparasites (via moxidectin). This dual action can simplify treatment protocols compared with using separate products, but selection should consider parasite prevalence, resistance patterns and individual animal health status.

Imoxat should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keep the container tightly closed and out of reach of children and animals. Do not freeze or expose the product to extreme temperatures.

Imoxat is typically applied topically to the skin or given orally, depending on the specific formulation supplied. The veterinarian will demonstrate the correct application site or oral dosing technique and advise on any necessary precautions during administration.

Serious risks include severe allergic reactions such as anaphylaxis, neurological signs like tremors or seizures, and profound gastrointestinal upset (e.g., hemorrhagic diarrhea). Owners should monitor treated animals closely and seek immediate veterinary care if any of these signs develop.

Imoxat should not be used in animals with known hypersensitivity to imidacloprid, moxidectin or any formulation components. It is also contraindicated in very young puppies or kittens (under eight weeks) and in breeding animals unless a veterinarian determines the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Imoxat (Imidacloprid;moxidectin)

Indications & Clinical Uses

How It Works